Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
08/2003
08/26/2003US6610729 Hydroxamic acid derivatives and medicinal utilization thereof
08/26/2003US6610728 Method for treatment of non-rheumatoid arthritis
08/26/2003US6610718 And dosage forms for treating rheumatoid arthritis
08/26/2003US6610716 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
08/26/2003US6610715 Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
08/26/2003US6610700 Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example
08/26/2003US6610698 Treatment of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interleukin-8 mediated diseases
08/26/2003US6610697 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
08/26/2003US6610695 Prophylaxis or treatment of CSBP/RK/p38 kinase mediated disease
08/26/2003US6610688 For therapy of blood vessel proliferative disorders; fibrotic disorders; mesangial cell proliferative disorders; metabolic disorders; allergies; asthma; thrombosis; nervous system diseases; and cancer
08/26/2003US6610683 Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
08/26/2003US6610676 Nitrate esters of corticoid compounds and pharmaceutical applications thereof
08/26/2003US6610523 Human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating
08/26/2003US6610510 Human Cerberus proteins and related nucleic acids are provided. Included are proteins comprising a human cerberus domain having specific activity, particularly the ability to antagonize a bone morphogenic protein. The proteins may be
08/26/2003US6610294 Methods of inhibiting an autoimmune response in a human suffering from an autoimmune disease by administering an antibody that binds to a protein to which monoclonal antibody 5C8 binds
08/25/2003CA2405347A1 Medicament comprising nk4 gene or recombinant nk4 protein
08/21/2003WO2003068937A2 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
08/21/2003WO2003068817A1 Management of mucosal viscosity by tff monomer peptides
08/21/2003WO2003068813A2 Group b streptococcus antigen
08/21/2003WO2003068812A2 Immune-modulating peptide made of s. aureus enterotoxin b
08/21/2003WO2003068811A2 Cytotoxic t-cell epitopes from chlamydia
08/21/2003WO2003068803A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003WO2003068769A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
08/21/2003WO2003068754A1 Therapeutic substituted indazole derivatives
08/21/2003WO2003068750A1 Jnk inhibitor
08/21/2003WO2003068747A1 Nicotinamide derivates useful as p38 inhibitors
08/21/2003WO2003068746A1 Aryl ureas as kinase inhibitors
08/21/2003WO2003068743A1 Chemical compounds
08/21/2003WO2003068252A1 Composition containing an extract of russian mumie for improving bone-growth and treating osteoporosis
08/21/2003WO2003068241A1 Percutaneous preparations
08/21/2003WO2003068235A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068234A1 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
08/21/2003WO2003068232A1 Nicotinamide derivatives useful as pde4 inhibitors
08/21/2003WO2003068230A1 Substituted pyridinones as modulators of p38 map kinase
08/21/2003WO2003068228A1 Aryl ureas with angiogenesis inhibiting activity
08/21/2003WO2003068225A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn$g(g)
08/21/2003WO2003068224A2 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003WO2003068223A1 Aryl ureas with raf kinase and angiogenesis inhibiting activity
08/21/2003WO2003068218A1 Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k
08/21/2003WO2003068210A1 N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
08/21/2003WO2003068208A1 Methods of reducing angiogenesis
08/21/2003WO2003068202A1 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
08/21/2003WO2003068171A2 Method and composition for treatment of inflammation and aids-associated neurological disorders
08/21/2003WO2003068146A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
08/21/2003WO2003068140A2 Novel pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same
08/21/2003WO2003067991A1 Compositions and methods for treatment of microbial infections
08/21/2003WO2003055913A3 Secreted protein
08/21/2003WO2003042245A3 Growth hormone variations in humans and their uses
08/21/2003WO2003027075A3 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
08/21/2003WO2003024935A3 Substituted pyrazolyl compounds for the treatment of inflammation
08/21/2003WO2003024474A3 Anti-inflammatory agent
08/21/2003WO2003020751A3 Homing peptides
08/21/2003WO2003007930A3 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
08/21/2003WO2002088664A3 Control of compactability through crystallization
08/21/2003WO2002085384A3 Lubricious coatings for substrates
08/21/2003WO2002068650A3 Modified and stabilized gdf propeptides and uses thereof
08/21/2003WO2002064748A3 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
08/21/2003WO2002058623A3 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation
08/21/2003WO2002057452A3 Human proteins, polynucleotides encoding them and methods of using the same
08/21/2003WO2002046158A3 Piperidine/piperazine-type inhibitors of p38 kinase
08/21/2003WO2002044209A3 Cytonkine receptor zcytor19
08/21/2003WO2002036611A3 Immunomodulatory peptides derived from heat shock proteins and uses thereof
08/21/2003WO2002020722A9 Methods and compositions for in vitro targeting
08/21/2003WO2001079479A3 Methods for selective targeting
08/21/2003US20030158602 Contacting a cell containing a NELL-1 gene with a test agent; and detecting a change in the expression level of Nell-1 gene as compared to the expression of the NELL-1 gene in a cell that is not contacted with test agent
08/21/2003US20030158414 Process for preparing growth hormone secretagogues
08/21/2003US20030158413 A thiochromane-7-carboxamide derivatives as Rho kinase enzyme inhibitor; nontoxic, anticancer agents
08/21/2003US20030158409 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
08/21/2003US20030158381 Novel insulin/igf/relaxin family polypeptides and dnas thereof
08/21/2003US20030158379 A DNA molecules encoding the proteins, used in the treatment of bone, connective tissue, tendon, ligament, wound healing and defects to tissues, animal growth factors, cell differentiation of embryonic and stem cells
08/21/2003US20030158266 Particularly septic shock
08/21/2003US20030158245 Fused heterocyclic derivatives, their production and use
08/21/2003US20030158241 Used for treatment of diabetes and a complication thereof, hyperlipidemia and a complication thereof, hyperuricemia, leukemia, and pancreatitis.
08/21/2003US20030158238 Treating diseases such as cancer, inflammatory disorders, restenosis,
08/21/2003US20030158225 Novel compounds
08/21/2003US20030158217 Succinate and malonate complexes treatment of abnormal cell growth, such as cancer, and overexpression of erbB2, and inducing cell death
08/21/2003US20030158189 Non-steroidal antiinflammatory agents treating bone disorders, Crohn's disease, and inflammatory bowel disease, respiratory disorders such as chronic obstructive pulmonary disease, infections, autoimmune diseases
08/21/2003US20030158187 Genetic polymorphisms in the preprotachy kinin gene
08/21/2003US20030158185 Novel use of phenylheteroakylamine derivatives
08/21/2003US20030158179 Quinoline derivatives
08/21/2003US20030158159 Administering a calcitonin-like agent and a dehydroepiandrosterone-like agent to treat an indivisual for bone density loss
08/21/2003US20030158125 Polysaccharidic esters of n-derivatives of glutamic acid
08/21/2003US20030158123 Purified material having size and growth inhibitory effects on cells and tissues
08/21/2003US20030158099 Cancer therapy
08/21/2003US20030157704 Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
08/21/2003US20030157560 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
08/21/2003US20030157225 Food product and process
08/21/2003US20030157179 Use of magnetic particles
08/21/2003US20030157144 Desaturase genes and uses thereof
08/21/2003US20030157108 80-100% of the glycoprotein has a mature core carbohydrate structure which lacks fucose, attached to a Fc region
08/21/2003US20030157094 Prevention, therapy liver disorders, inflammatory bowel diseases, Crohn's disease; antiulcer agents; rheumatic diseases
08/21/2003US20030157084 Methods for preparing purified prostaglandin E synthase
08/21/2003US20030157078 Identification of a pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell
08/21/2003CA2476553A1 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
08/21/2003CA2476454A1 Use of inhibitors of the sodium-dependent chloride-bicarbonate-exchanger for treating thrombotic and inflammatory diseases
08/21/2003CA2476239A1 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
08/21/2003CA2476162A1 Jnk inhibitor
08/21/2003CA2475838A1 Cytotoxic t-cell epitopes from chlamydia
08/21/2003CA2475770A1 Microglia inhibitors for interrupting immune reactions induced by interleukin 12 and ifn.gamma.g(g)
08/21/2003CA2475708A1 Nicotinamide derivatives useful as pde4 inhibitors
1 ... 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 ... 820